PRKCDBP Antibody

Product Specifications

Background

PRKCDBP Antibody: The protein kinase C delta (PKC-δ ) binding protein (PRKCDBP), also known as cavin-3, is a member of the cavin family of proteins that are involved in caveolin formation and regulation. PRKCDBP was initially identified in a screen of cultured cell lines for proteins that were strongly induced by serum starvation. Studies indicate that PRKCDBP binds not only to PKC-δ but also to caveolin-1 and helps regulate caveolin traffic and function. Similar to other members of the cavin family, the expression of PRKCDBP was found to be down-regulated in various cancer cell lines, suggesting a possible tumor suppressor function of PRKCDBP.

NCBI Gene ID

112464

Swiss Prot

Q969G5

Accession Number

NP_659477

Host

Rabbit

Reactivity

Human, Mouse

Clonality

Polyclonal

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Cancer, Cell Cycle

Purification

PRKCDBP Antibody is affinity chromatography purified via peptide column.

Positive Control

Cat. No. 1288 - A20 Cell Lysate

Concentration

1 mg/mL

Homology

Predicted species reactivity based on immunogen sequence: Rat: (100%)

Buffer

PRKCDBP Antibody is supplied in PBS containing 0.02% sodium azide.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

PRKCDBP antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year.

Calculated Molecular Weight

29 kDa

Fragment

IgG

Specificity

It is predicted to not cross-react with other members of the cavin family.

Symbol

PRKCDBP

Positive Control 2

Cat. No. 10-901 - Human Spleen Tissue Slide

NCBI Official Name

Protein kinase C, delta binding protei

NCBI Organism

Homo sapiens

Background Reference 01

Briand N, Dugail I, and Le Lay S. Cavin proteins: New players in the caveolae field. Biochimie 2011; 93:71-7.

Background Reference 02

Izumi Y, Hirai S, Tamai Y, et al. A protein kinase Cdelta-binding protein SRBC whose expression is induced by serum starvation. J. Biol. Chem. 1997; 272:7381-9.